Pomalidomide
Blood Protein Disorders
Hellenic Society of HematologySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Blood Protein Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Hellenic Society of Hematology | Phase 3 | BB |
cc-5013 Hellenic Society of Hematology | Phase 3 | BB |
Cyclophosphamide Hellenic Society of Hematology | Phase 2 | CCC |
Isatuximab Hellenic Society of Hematology | Phase 2 | CCC |
Bortezomib Hellenic Society of Hematology | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Pomalidomide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →